Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 15 vs LEXAPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
Initial 5 mg orally once daily; maximum 10 mg once daily.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 15 vs LEXAPRO, answered by our medical review team.
ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 15 and LEXAPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 15 and LEXAPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.